Ceftriaxone Sodium
Brand names: Ceftriaxone
At a glance
- Medicare prescriptions, 2024
- 237,046
- Medicare drug cost
- $14.6M
- Average cost per prescription
- $61.47
- Clinicians who prescribed it
- 8,034
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Before instituting treatment with Ceftriaxone Injection, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone Injection and other antibacterial drugs, Ceftriaxone Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone Injection is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing…
From the FDA-approved prescribing information (label dated October 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Infectious Disease 35.4%
- Internal Medicine 19.4%
- Nurse Practitioners 16.8%
- Family Medicine 15.1%
- Geriatric Medicine 3.0%
- Physician Assistants 2.6%
- Hospitalist 1.5%
- General Practice 1.5%
- Urology 1.1%
- Hospice & Palliative Medicine 0.4%
- Emergency Medicine 0.3%
- Physical Medicine & Rehabilitation (PM&R) 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 13% from 2019 to 2024.
Biggest change by state since 2019
- Virginia +39%
- Illinois +27%
- Florida +25%
- Kentucky +23%
- Arkansas +22%
- Massachusetts (smallest change) −7%
- Alabama (smallest change) −6%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.